L-697,661 + zidovudine

L-697,661 + zidovudine is a combination of two antiretroviral drugs investigated for the treatment of HIV-1 infection. L-697,661 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of the pyridinone class that selectively targets HIV-1 reverse transcriptase, while zidovudine (also known as AZT) is a nucleoside reverse transcriptase inhibitor (NRTI). The combination leverages two distinct mechanisms of inhibiting reverse transcriptase, aiming to improve antiviral efficacy and delay emergence of drug resistance. Clinical studies have demonstrated that combination therapy mitigates the selection of HIV-1 variants highly resistant to L-697,661 which can rapidly emerge with monotherapy[1][2][3][5].

Other names

L-697661 + AZTL-697,661 + AZT